In a significant milestone for global health, the first-ever malaria treatment specifically designed for babies has been cleared for use. The innovative drug, known as Coartem Baby, is anticipated to be introduced in African countries within weeks. Until now, infants suffering from malaria have been treated with medications formulated for older children, which posed the risk of overdose due to the different ways babies process medicine. Tragically, malaria has been linked to around 597,000 deaths in 2023, with most casualties occurring in Africa and disproportionately affecting children under five.
Developed by Novartis, in partnership with the Medicines for Malaria Venture (MMV), Coartem Baby is a major step forward in addressing this "treatment gap," as explained by health experts. The dosage is optimized for newborns and younger babies, providing much-needed treatment options for this vulnerable group. Novartis plans to introduce the drug primarily on a not-for-profit basis, ensuring thousands of babies can finally receive effective care.
Leaders from MMV and health authorities expressed their hope that this breakthrough will not only save lives but also contribute to the broader goal of eliminating malaria in future generations.
Developed by Novartis, in partnership with the Medicines for Malaria Venture (MMV), Coartem Baby is a major step forward in addressing this "treatment gap," as explained by health experts. The dosage is optimized for newborns and younger babies, providing much-needed treatment options for this vulnerable group. Novartis plans to introduce the drug primarily on a not-for-profit basis, ensuring thousands of babies can finally receive effective care.
Leaders from MMV and health authorities expressed their hope that this breakthrough will not only save lives but also contribute to the broader goal of eliminating malaria in future generations.
